Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
Full name:
Authorised dose form:
Legal status of supply:
Domain:
Resource status:
Product classification:
Document Details
Generated Narrative: Bundle TEST PURPOSES ONLY - lixiana
Language: en
Profile: Bundle - ePI
Final Document at 2022-02-16 13:28:17+0000 by Organization ACME industry for Bundle: identifier = http://ema.europa.eu/identifier#None; type = document; timestamp = 2023-06-27 10:09:22+0000
Document Subject
Generated Narrative: MedicinalProductDefinition mpf4481348d9114628b637efdc170b1539
identifier: http://ema.europa.eu/identifier
/EU/1/15/993/001, EU/1/15/993/016
type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Lixiana 15 mg film-coated tablets
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en
Document Content
Generated Narrative: Composition composition-en-f4481348d9114628b637efdc170b1539
Language: en
Profile: Composition (ePI)
identifier: http://ema.europa.eu/identifier
/EU/1/15/993/001, EU/1/15/993/016
status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - lixiana
Mode | Time |
Official | 2022-02-16 13:28:17+0000 |
What is in this leaflet
Lixiana contains the active substance edoxaban and belongs to a group of medicines called anticoagulants. This medicine helps to prevent blood clots from forming. It works by blocking the activity of factor Xa, which is an important component of blood clotting.
Lixiana is used in adults to:
Do not take Lixiana
Warnings and precautions
Talk to your doctor or pharmacist before taking Lixiana,
Lixiana 15 mg is only to be used when changing from Lixiana 30 mg to a vitamin K antagonist (e.g. warfarin) (see section
Take special care with Lixiana,
If you need to have an operation,
Children and adolescents
Lixiana is not recommended in children and adolescents under 18 years of age.
Other medicines and Lixiana
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
If you are taking any of the following:
If any of the above apply to you, tell your doctor before taking Lixiana, because these medicines may increase the effects of Lixiana and the chance of unwanted bleeding. Your doctor will decide, if you should be treated with Lixiana and if you should be kept under observation.
If you are taking any of the following:
Pregnancy and breast-feeding
Do not take Lixiana if you are pregnant or breast-feeding. If there is a chance that you could become pregnant, use a reliable contraceptive while you are taking Lixiana. If you become pregnant while you are taking Lixiana, immediately tell your doctor, who will decide how you should be treated.
Driving and using machines
Lixiana has no or negligible effects on your ability to drive or use machines.
Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.
How much to take
The recommended dose is one 60 mg tablet once daily.
How to take the tablet
Swallow the tablet, preferably with water. Lixiana can be taken with or without food.
If you have difficulty swallowing the tablet whole, talk to your doctor about other ways to take Lixiana. The tablet may be crushed and mixed with water or apple puree immediately before you take it. If necessary, your doctor may also give you the crushed Lixiana tablet through a tube via the nose (nasogastric tube) or a tube in the stomach (gastric feeding tube).
Your doctor may change your anticoagulant treatment as follows:
Changing from vitamin K antagonists (e.g. warfarin) to Lixiana Stop taking the vitamin K antagonist (e.g. warfarin). Your doctor will need to do blood measurements and will instruct you when to start taking Lixiana.
Changing from non-VKA oral anticoagulants (dabigatran, rivaroxaban, or apixaban) to Lixiana Stop taking the previous medicines (e.g. dabigatran, rivaroxaban, or apixaban) and start Lixiana at the time of the next scheduled dose.
Changing from parenteral anticoagulants (e.g. heparin) to Lixiana Stop taking the anticoagulant (e.g. heparin) and start Lixiana at the time of the next scheduled anticoagulant dose.
Changing from Lixiana to vitamin K antagonists (e.g. warfarin) If you currently take 60 mg Lixiana: Your doctor will tell you to reduce your dose of Lixiana to a 30 mg tablet once daily and to take it together with a vitamin K antagonist (e.g. warfarin). Your doctor will need to do blood measurements and will instruct you when to stop taking Lixiana. If you currently take 30 mg (dose reduced) Lixiana: Your doctor will tell you to reduce your dose of Lixiana to a 15 mg tablet once daily and to take it together with a vitamin K antagonist (e.g. warfarin). Your doctor will need to do blood measurements and will instruct you when to stop taking Lixiana.
Changing from Lixiana to non-VKA oral anticoagulants (dabigatran, rivaroxaban, or apixaban) Stop taking Lixiana and start the non-VKA anticoagulant (e.g. dabigatran, rivaroxaban, or apixaban) at the time of the next scheduled dose of Lixiana.
Changing from Lixiana to parenteral anticoagulants (e.g. heparin) Stop taking Lixiana and start the parenteral anticoagulant (e.g. heparin) at the time of the next scheduled dose of Lixiana.
Patients undergoing cardioversion:
If your abnormal heartbeat needs to be restored to normal by a procedure called cardioversion, take Lixiana at the times your doctor tells you to prevent blood clots in the brain and other blood vessels in your body.
If you take more Lixiana than you should
Tell your doctor immediately if you have taken too many Lixiana tablets. If you take more Lixiana than recommended, you may have an increased risk of bleeding.
If you forget to take Lixiana
You should take the tablet immediately and then continue the following day with the once daily tablet as usual. Do not take a double dose on the same day to make up for a forgotten dose.
If you stop taking Lixiana
Do not stop taking Lixiana without talking to your doctor first, because Lixiana treats and prevents serious conditions.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Like other similar medicines (medicines to reduce blood clotting), Lixiana may cause bleeding which may potentially be life-threatening. In some cases the bleeding may not be obvious.
If you experience any bleeding event that does not stop by itself or if you experience signs of excessive bleeding (exceptional weakness, tiredness, paleness, dizziness, headache or unexplained swelling) consult your doctor immediately.
Your doctor may decide to keep you under closer observation or change your medicine.
Overall list of possible side effects:
Common (may affect up to 1 in 10 people)
Uncommon (may affect up to 1 in 100 people)
Rare (may affect up to 1 in 1,000 people)
Not known (frequency cannot be estimated from the available data)
Reporting of side effects
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and on each blister or bottle after EXP. The expiry date refers to the last day of that month.
This medicine does not require any special storage conditions.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
Entry 1 - fullUrl = Composition/composition-en-f4481348d9114628b637efdc170b1539
Resource Composition:
Generated Narrative: Composition composition-en-f4481348d9114628b637efdc170b1539
Language: en
Profile: Composition (ePI)
identifier:
http://ema.europa.eu/identifier
/EU/1/15/993/001, EU/1/15/993/016status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - lixiana
Attesters
Mode Time Official 2022-02-16 13:28:17+0000
Entry 2 - fullUrl = MedicinalProductDefinition/mpf4481348d9114628b637efdc170b1539
Resource MedicinalProductDefinition:
Generated Narrative: MedicinalProductDefinition mpf4481348d9114628b637efdc170b1539
identifier:
http://ema.europa.eu/identifier
/EU/1/15/993/001, EU/1/15/993/016type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Lixiana 15 mg film-coated tablets
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en